Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients
Abstract Patients with type 2 diabetes mellitus (T2DM) and obesity are at high risk of developing cardiovascular disease (CVD). Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter (SGLT-2) inhibitors have been shown to prevent CVD in T2DM patients. Additionall...
Main Authors: | Kazushi Uneda, Yuki Kawai, Takayuki Yamada, Sho Kinguchi, Kengo Azushima, Tomohiko Kanaoka, Yoshiyuki Toya, Hiromichi Wakui, Kouichi Tamura |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-05-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-89620-7 |
Similar Items
-
Effects of Single Pill-Based Combination Therapy of Amlodipine and Atorvastatin on Within-Visit Blood Pressure Variability and Parameters of Renal and Vascular Function in Hypertensive Patients with Chronic Kidney Disease
by: Kengo Azushima, et al.
Published: (2014-01-01) -
Effects of Erythropoietin-Stimulating Agents on Blood Pressure in Patients with Non-Dialysis CKD and Renal Anemia
by: Kohji Ohki, et al.
Published: (2020-06-01) -
Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis
by: Takayuki Yamada, et al.
Published: (2021-01-01) -
Bofu-tsu-shosan, an oriental herbal medicine, exerts a combinatorial favorable metabolic modulation including antihypertensive effect on a mouse model of human metabolic disorders with visceral obesity.
by: Kengo Azushima, et al.
Published: (2013-01-01) -
L/N-Type Calcium Channel Blocker Cilnidipine Added to Renin-Angiotensin Inhibition Improves Ambulatory Blood Pressure Profile and Suppresses Cardiac Hypertrophy in Hypertension with Chronic Kidney Disease
by: Satoshi Umemura, et al.
Published: (2013-08-01)